Easy Online Management Tool with PATHwatch™

PAH Pathways Interactive Resource Locator

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more »

PATHwatch: Save time and paperwork by accessing secure and instant patient information

With our online patient management tool, you can gain instant and important information about your patients taking Tracleer^® (bosentan) or Ventavis^® (iloprost).

PATHwatch is provided exclusively by Actelion and at no cost to healthcare professionals.

Access in-depth status reports 24 hours a day: Quickly access your patient profiles, including enrollment dates, shipment history, insurance information, and patient status.

Monitor shipments quickly with point-and-click ease: See which specialty pharmacy is servicing your patient, review status of patient enrollment and shipments including past shipment archives.

Identify all your patients at a glance: Search for patients or groups of patients via customized data searching, sorting and filtering.

Register today and start saving time and paperwork:

Call toll-free 1-866-ACTELION (228-3546) or download the PATHwatch User Registration form and fax to: 1-866-279-0669. Your username and password will arrive via secure delivery in 3 to 5 business days.

Ventavis Indication:

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

Ventavis Important Safety Information:

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information for Ventavis.

Tracleer Indication:

Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital systemic-to-pulmonary shunts (18%).

Considerations for use
Patients with WHO class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of liver injury in WHO class II patients, which may preclude future use as their disease progresses.

Please see full Prescribing Information, including BOXED WARNING about liver injury and pregnancy.